Hi [[ session.user.profile.firstName ]]

Rapid T Cell Human Immune System ImmunoGraft® Platform to test PD of IOTherapy

Champions Oncology was excited to participate in the American Association of Cancer Research’s (AACR) Virtual Meeting in June. Due the limited availability of access to these posters, we wanted to give you direct access to our expert researchers and all the details of the newest innovations happening at Champions. Therefore, we have set up Poster Talks with each presenter so that you can register, attend and ask questions live during each session – just like you were at AACR2020 face-to-face. The key poster takeaways you will learn by watching this webinar are:
•Learning more about Champions Oncology’s T cell ImmunoGraft® platform and it’s applications in vivo using CDX and PDX.
•Engraftment and infiltration of T cells in CDX and PDX models.
•Expression of costimulatory and inhibitory markers in the platform.
Live online Aug 12 2:00 pm UTC
or after on demand 30 mins
Your place is confirmed,
we'll send you email reminders
Presented by
Bhavna Verma, PhD, Scientist II, ImmunoOncology Department, Champions Oncology
Presentation preview: Rapid T Cell Human Immune System ImmunoGraft® Platform to test PD of IOTherapy

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
  • Establishment of a Patient-derived B-ALL Ex Vivo Platform Aug 18 2020 2:00 pm UTC 30 mins
    Bandana Vishwakarma, PhD, Scientist in Hematology Oncology at Champions Oncology
    Champions Oncology was excited to participate in the American Association of Cancer Research’s (AACR) Virtual Meeting in June. Due the limited availability of access to these posters, we wanted to give you direct access to our expert researchers and all the details of the newest innovations happening at Champions. Therefore, we have set up Poster Talks with each presenter so that you can register, attend and ask questions live during each session – just like you were at AACR2020 face-to-face. The key poster takeaways you will learn by watching this webinar are:
    •Phenotyping, media optimization and reproducibility in B-ALL Models.
    •2D B-ALL platform and its applications with therapeutic agents.
    •Coculturing of B-ALL cells with BM-MSC and its impact.
  • Rapid T Cell Human Immune System ImmunoGraft® Platform to test PD of IOTherapy Aug 12 2020 2:00 pm UTC 30 mins
    Bhavna Verma, PhD, Scientist II, ImmunoOncology Department, Champions Oncology
    Champions Oncology was excited to participate in the American Association of Cancer Research’s (AACR) Virtual Meeting in June. Due the limited availability of access to these posters, we wanted to give you direct access to our expert researchers and all the details of the newest innovations happening at Champions. Therefore, we have set up Poster Talks with each presenter so that you can register, attend and ask questions live during each session – just like you were at AACR2020 face-to-face. The key poster takeaways you will learn by watching this webinar are:
    •Learning more about Champions Oncology’s T cell ImmunoGraft® platform and it’s applications in vivo using CDX and PDX.
    •Engraftment and infiltration of T cells in CDX and PDX models.
    •Expression of costimulatory and inhibitory markers in the platform.
  • Custom immune assessment using flow cytometry to support clinical development Aug 4 2020 2:00 pm UTC 30 mins
    Greg Bannish, PhD, Subject Matter Expert - Flow Cytometry, Champions Oncology
    Champions Oncology was excited to participate in the American Association of Cancer Research’s (AACR) Virtual Meeting in June. Due the limited availability of access to these posters, we wanted to give you direct access to our expert researchers and all the details of the newest innovations happening at Champions. Therefore, we have set up Poster Talks with each presenter so that you can register, attend and ask questions live during each session – just like you were at AACR2020 face-to-face. The key poster takeaways you will learn by watching this webinar are:
    •Considerations for immune assessment during clinical drug development
    •Key factors in a successful flow cytometry assay
    •Validation overview for flow cytometry assays to support clinical trials
    •Case study: development and validation of a 19 color human T cell panel
  • 2D Ex Vivo Patient-derived AML Platform for testing Molecular-Targeted Therapies Recorded: Jul 28 2020 22 mins
    Bandana Vishwakarma, PhD, Scientist in Hematology Oncology at Champions Oncology
    Champions Oncology was excited to participate in the American Association of Cancer Research’s (AACR) Virtual Meeting in June. Due the limited availability of access to these posters, we wanted to give you direct access to our expert researchers and all the details of the newest innovations happening at Champions. Therefore, we have set up Poster Talks with each presenter so that you can register, attend and ask questions live during each session – just like you were at AACR2020 face-to-face. The key poster takeaways you will learn by watching this webinar are:
    •Phenotyping, media optimization and reproducibility in AML models.
    •2D AML platform and its applications evaluating small molecule inhibitors.
    •Ex vivo and in vivo sensitivity to Ara-C.
  • Novel Applications for Ex Vivo PDX Models of the Tumor Microenvironment Recorded: Jul 22 2020 57 mins
    Chris Koehler, PhD, Director of Scientific Operations at PhenoVista Biosciences
    Ex Vivo platforms not only can be used to gather additional in vivo model data throughout the in-life portion of an oncology study as well as at study completion, they also can address mechanisms of action for immuno-oncology agents and test for cytotoxicity of oncology therapeutics in an ex vivo system. In this webinar, case studies will be presented to demonstrate physiologically relevant 2D and 3D ex vivo PDX Models.

    Register for this webinar to learn:
    •How to combine physiologically relevant 2D and 3D ex vivo PDX models with quantitative fluorescence imaging and luminescence assays.
    •Why Use Tumor Fragments vs. Other 3D Systems?
    •How ex vivo PDX models more accurately reflect tumor heterogeneity and in vivo microenvironment using a tumor fragment approach.
    •How incorporating a diversity of readouts, including industry standard CellTiter Glo + fluorescence microscopy, can provide additional insights to drive research programs forward.
    •How adapting design flexibility, including drug combinations, treatment length, assay timing (3 days to 21-day assays) and readouts (RNA/Protein isolation) can improve data richness.
  • Myeloid Cell Conundrum in Inflammation and Cancer Recorded: Jul 15 2020 60 mins
    Pravesh Gupta,PhD, Postdoctoral Fellow at Krishna Bhat's Lab at MD Anderson
    The field of Myeloid biology has changed dramatically, especially in the oncology area. Flow Cytometry is a critical tool that can be utilized to better understand myeloid biology and the cell's involvement in cancer. In this webinar, Dr. Pravesh Gupta, of MD Anderson Cancer Center, will share his expertise in myeloid biology and working to develop flow cytometry assays in the oncology space.

    Register for this webinar to learn:
    •Heterogeneity of myeloid cells beyond M1/M2
    •Cytometry based experimental designs to delineate myeloid cells
    •Single-cell technologies sculpting the myeloid landscape in cancer
  • NK Human Immune System ImmunoGraft® Platform to Evaluate the PD of IO Therapies Recorded: Jul 14 2020 28 mins
    Bhavna Verma, PhD, Scientist II, ImmunoOncology Department, Champions Oncology
    Champions Oncology was excited to participate in the American Association of Cancer Research’s (AACR) Virtual Meeting in June. Due the limited availability of access to these posters, we wanted to give you direct access to our expert researchers and all the details of the newest innovations happening at Champions. Therefore, we have set up Poster Talks with each presenter so that you can register, attend and ask questions live during each session – just like you were at AACR2020 face-to-face. The key poster takeaways you will learn by watching this webinar are:
    •Learning more about Champions Oncology’s NK ImmunoGraft® platform and it’s applications in vivo using CDX and PDX.
    •Ex vivo expansion of NK cells and their functionality.
    •Engraftment using ex vivo expanded and primary NK cells.
  • LUMIN: Harnessing the Power of Pharmaco-omics to Illuminate Tumor Cell Biology Recorded: Jun 18 2020 49 mins
    Michael Ritchie, PhD, MBA, Champions Oncology, Chief Commercial Officer
    Data drives every great discovery in modern-day science. At Champions Oncology, we deliver innovative solutions to accelerate oncology drug development. Lumin is that innovative solution. Lumin is a revolutionary data interpretation software capable of analyzing proteomic, genomic and transcriptomic datasets in real time, giving scientists novel insights at their fingertips. The power of Lumin is in the ability to explore data assembled from over 13,000 cancer patients, including thousands of clinical treatment responses not available in any public dataset. In this webinar, case studies will be presented to demonstrate the many different ways to use our newest bioinformatics solution, Lumin.

    Register for this webinar to learn more about Lumin and:
    •Analyze pharmaco-omic relationships across 13,000+ datasets, including Champions’ PDX compendium of 1000 tumor models with known clinical responses.
    •Use external processed pharmaco-omic data for a personalized experience.
    •Investigate gene signatures and biomarker pathways to discover new hypotheses.
  • Next Generation Humanized Mice for AML and NK Cell Therapy Testing Recorded: Jun 8 2020 55 mins
    Amy Wesa, PhD, Director of Immuno-Oncology Research at Champions Oncology
    To develop the most successful novel agents for cancer, researchers require preclinical models that fundamentally epitomize patient populations to enable predictive outcomes. Patient-derived models represent a considerable advantage over traditional models of cancer to expedite drug development. In this webinar, Amy Wesa, PhD, of Champions Oncology Inc, will discuss how complementing these translational PDX models with the introduction of human immune cells is driving the next generation of patient-derived models. View this webinar to learn: The latest advances in human immune system mouse models for oncology therapeutics The power of primary patient-derived models for acute myeloid leukemia (AML) Novel methods for evaluating natural killer (NK) cell therapeutics of cancer in humanized mice
  • Flow Cytometry: Validation and Implementation in a Regulatory Setting Recorded: May 28 2020 56 mins
    Chelsea Riveley, MBA, Head of Business Development, Flow Cytometry Services
    This webinar provides an overview of flow cytometry and its potential uses in the regulatory setting. Two case studies will be presented to detail the unique aspects of conducting flow cytometry in both a preclinical and clinical regulated setting. The following phases of developing and validating a robust and reliable flow cytometry assay will be illustrated in this webinar: The critical steps to any flow cytometry assay – panel design, assay development, descriptions of validation test scripts that should be conducted along with suitable acceptance criteria, proper instrument set-up and appropriate controls, gating strategy and identification of cell subsets, and correct interpretation of flow cytometry data. Lastly, what to look for when choosing an outsourcing partner for flow cytometry will be discussed. These include some of the key decision points and factors to consider such as expertise, regulatory requirements, logistics, timelines, and price.
  • It’s in the blood: Patient-derived hematologic malignancy models in research Recorded: May 14 2020 35 mins
    Amy Wesa, PhD, Director of Immuno-Oncology Research, Champions Oncology
    Hematological malignancies are cancers that begin in the cells of blood-forming tissue or in the cells of the immune system. These types of cancer, specifically, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and Multiple Myeloma (MM) are on the rise in the aging population globally. In this webinar, Dr. Wesa will demonstrate how patient-derived hematologic malignancy in vivo and ex vivo models can be used to advance drug development.

    Viewing this webinar will help you to:
    •Develop an understanding of a robust approach to human AML Patient-derived Xenograft (PDX) in vivo models
    •Learn how to select study endpoints for in vivo and ex vivo models
    •Learn how to advance early stage compounds through Champions’ hematologic Vitroscreen for AML, B-ALL and MCL Disease indications
  • Designing Cytometry Assays for IO Applications: The Do's, Don'ts & Don't Forgets Recorded: Apr 30 2020 61 mins
    Dr. Tamara Laskowski, Senior Research Scientist of MD Anderson Cancer Center
    For many researchers flow cytometry can be overwhelming and confusing, especially if this is a technique is not used every day. In this webinar, Dr. Tamara Laskowski, of MD Anderson Cancer Center, will share her expertise in working to develop practical flow cytometry assays in the Immuno-Oncology area.

    Register for this webinar to learn:
    •The requirements for design and development of cytometry-based assays
    •Strategies for increasing reproducibility of flow cytometry assays
    •Important considerations when designing cytometry-based assays for immuno-oncology studies
  • Next Generation Humanized Mice for AML and NK Cell Therapy Testing Recorded: Apr 13 2020 56 mins
    Amy Wesa, PhD, Director of Immuno-Oncology Research at Champions Oncology
    To develop the most successful novel agents for cancer, researchers require preclinical models that fundamentally epitomize patient populations to enable predictive outcomes. Patient-derived models represent a considerable advantage over traditional models of cancer to expedite drug development. In this webinar, Amy Wesa, PhD, of Champions Oncology Inc, will discuss how complementing these translational PDX models with the introduction of human immune cells is driving the next generation of patient-derived models. View this webinar to learn: The latest advances in human immune system mouse models for oncology therapeutics The power of primary patient-derived models for acute myeloid leukemia (AML) Novel methods for evaluating natural killer (NK) cell therapeutics of cancer in humanized mice
  • PDX Programs for Clinical Advancement of Oncology Agents Recorded: Apr 13 2020 55 mins
    Neal Goodwin, PhD, Vice President of Research Development
    The Champions TumorGraft platform is being used for conducting high throughput translational medicine trials across a multitude of patient tumor models, including AML and ALL. This informative webinar will specifically cover introduction to the PDX algorithm, overview of the Champions Oncology PDX tumor bank, overview of the Champions Oncology co-clinical program, AML modeling, CD34+ HSC-derived humanized PDX models for immunotherapy testing.
  • Advanced Hematology Oncology PDX Tumor Biology Platforms for Drug Advancement Recorded: Apr 13 2020 45 mins
    Neal Goodwin, PhD, Vice President of Research Development
    Champions Oncology has established an advanced PDX platform for modeling hematology oncology malignancies, including AML and ALL. The resource consists of leukaphresis AML and ALL clinical patient samples that are characterized for the ability to engraft into P1 study mice. Additionally a resource for modeling define patient populations as they progress co-clinically has been created by collecting blasts from patients as they progress in the clinic. Both approaches are advantageous with the leukaphresis resource allowing for modeling large numbers of study mice across an established panel of patient samples and the co-clinical resource for modeling defined patient cohorts co-clinically.
Webinars for Pharmaceutical and Biotech Researchers
Champions Oncology delivers innovative solutions to oncology drug development, accelerating the journey from the research bench to the clinic – decreasing timelines, lowering costs, and ultimately saving patient lives. Learn more about Champions Oncology's capabilities, our service platforms and educational topics affecting our industry on our Webinar Channel.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Rapid T Cell Human Immune System ImmunoGraft® Platform to test PD of IOTherapy
  • Live at: Aug 12 2020 2:00 pm
  • Presented by: Bhavna Verma, PhD, Scientist II, ImmunoOncology Department, Champions Oncology
  • From:
Your email has been sent.
or close